Newsroom

Three intestinal organoids (gray) with spreading Shigella infection (green)

News

Thanks to lab-grown miniature intestines, researchers at the Helmholtz Institute for RNA-based Infection Research (HIRI) in Würzburg in collaboration with Uppsala University in Sweden have successfully mapped how aggressive Shigella bacteria infect the human gut. The study, published today in the journal Nature Genetics, opens the door to using cultured human mini-organs to investigate a wide range of other serious infections.

12.06.2025

HIRI

News

New, resistance-breaking drugs are urgently needed to effectively treat infections with antibiotic-resistant germs in the future. Researchers from Saarbrücken and Vienna have now found a possible starting point for the development of such drugs in the natural product Saarvienin A. This novel molecule is capable of killing bacteria even if they are already resistant to clinically used antibiotics. The researchers published their findings in the journal Angewandte Chemie International Edition.

28.05.2025

HIPS

HZI podcast "InFact" with Theresa Graalmann on the topic autoimmune diseases

News

When our immune system chooses the wrong enemy and turns against our own body, autoimmune diseases can result. Dr. Dr. Theresa Graalmann is a physician and clinician scientist who heads the junior research group “Translational Immunology” at TWINCORE – Center for Experimental and Clinical Infection Research. In this episode of the HZI podcast InFact, she explains how rheumatism, lupus, and vascular inflammation develop and how doctors and scientists work together to incorporate patient data and state-of-the-art cell analyses directly into the development of new therapeutic approaches.

27.05.2025

TWINCORE

Study authors Maureen Obara and Dr Matthias Bruhn

News

Monoclonal antibodies against SARS-CoV-2 were considered a promising approach for the prevention and therapy of corona virus infections. However, the ongoing evolution of the virus regularly produces new variants that are no longer neutralized by the antibodies. Researchers from TWINCORE, together with partners from Hanover and Bern, have now been able to clarify the underlying mechanism in more detail. The TWINCORE is a joint institution of the Helmholtz Centre for Infection Research (HZI) in Braunschweig and Hannover Medical School (MHH). Instead of using a single antibody, they propose the combination of several antibodies for treatment. They have published their findings in the scientific journal eBioMedicine.

26.05.2025

TWINCORE

News

Decisions have been made on future Clusters of Excellence in the second round of competition under the Excellence Strategy – the joint initiative of the federal and state governments to further strengthen top-level research at universities in Germany. The Helmholtz Centre for Infection Research (HZI) is part of two of the funded Clusters of Excellence together with university partners: RESIST and NUCLEATE. RESIST at Hannover Medical School (MHH) will receive funding for another seven years. In this cluster, scientists are investigating how people who are susceptible to infection can be better protected. In the newly approved NUCLEATE cluster at the Julius-Maximilians-Universität Würzburg (JMU) with the Technical University of Munich and the Ludwig-Maximilians-Universität München, group leaders from the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the HZI in cooperation with the JMU, are conducting research into nucleic acid-based therapies. A total of 70 Clusters of Excellence were selected for funding.

26.05.2025

HZI Campus

TWINCORE

CiiM

HIRI

News

Bats are known as natural hosts for highly pathogenic viruses such as MERS- and SARS-related coronaviruses, as well as the Marburg and Nipah viruses. In contrast to the severe and often fatal disease outcomes these viruses cause in humans, bats generally do not show obvious signs of viral illness following infection. An international research team led by Dr. Max Kellner and Prof. Josef Penninger, Scientific Director of the Helmholtz Centre for Infection Research (HZI), has developed an innovative organoid research platform that allowed them to closely investigate the cellular antiviral defense mechanisms of mucosal epithelial tissues of bats. The results have now been published in Nature Immunology and could pave the way for the development of new therapies against viral diseases.

21.05.2025

HZI Campus

Back to the first page
...
15
16
17
18
...
156

HZI in the media

20.04.2026

World Organisation for Animal Health

20.04.2026

Springer

... Helmholtz-Zentrum für Infektionsforschung

02.09.2025 12:36

DLR Projektträger

02.10.2025 07:49 ...

17.04.2026

Informations Dienst Wissenschaft

Wissenschaftler des Max-Delbrück-Centrums und des Helmholtz-Zentrums für Infektionsforschung haben eine umfassende Protein-Karte von

17.04.2026

IT Boltwise

16.04.2026

Bionity.COM

In January 2023, researchers at the Helmholtz Institute for One Health in Germany noticed that an infant monkey known as a sooty mangabey

15.04.2026

New Atlas

at the Helmholtz Institute for RNA-based Infection Research (HIRI), a site of the Braunschweig Helmholtz Center for Infection Research (HZI)

14.04.2026

Phys.org

... der Infektion und Nozizeption“ am Helmholtz-Zentrum für Infektionsforschung (HZI) in Braunschweig. Nozizeption ist der Fachbegriff ...

14.04.2026

Verband Deutscher Biologen e.V.

... recht nicht bei Fabian Leendertz, der in Greifswald das „Helmholtz-Institut für One Health“ leitet. Im ...

14.04.2026

FAZ.NET

... sich auch das Helmholtz-Institut für Pharmazeutische Forschung Saarland ( HIPS ), das Helmholtz-Zentrum für Infektionsforschung ( HZI ) ...

09.04.2026

Deutsches Ärzteblatt

... ÖAW in Wien und nun Gruppenleiter am Helmholtz Zentrum für Infektionsforschung in Braunschweig, forscht an ...

08.04.2026

DerStandard.de

... group within the Microstar Program at the Helmholtz Centre for Infection Research (HZI) and a ...

31.03.2026

Informations Dienst Wissenschaft

Register now for the HZI-Newsletter

and stay up to date!

Email address *

We use rapidmail to send our newsletter. I agree that my data entered here will be transmitted to rapidmail. I have taken note of the HZI's privacy policy and have been informed of my rights.